Evidence map›Paper›PMID 40741254›Full record

ArticleArchives of medical science : AMS2025

A 360° perspective on cardiovascular prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE).

Maciej Banach, Federica Fogacci, Atanas G Atanasov, Anca Pantea Stoian, Jacek Jóźwiak, Ibadete Bytyçi, Ivan Pećin, Niki Katsiki, Mohsen Mazidi, Ioanna Gouni-Berthold and 4 more

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maciej BanachCenter for Atherosclerosis and Cardiovascular Diseases Prevention, Collegium Medicum, John Paul II Catholic University of Lublin, Lublin, Poland.
Federica FogacciHypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Atanas G AtanasovInstitute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Magdalenka, Poland.
Anca Pantea StoianDepartment of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Jacek JóźwiakDepartment of Family Medicine and Public Health, Institute of Medical Sciences, University of Opole, Poland.
Ibadete BytyçiClinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo.
Ivan PećinDepartment of Internal Medicine, Division of Metabolic Diseases, University Hospital Center Zagreb, Zagreb, Croatia.
Niki KatsikiDepartment of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.
Mohsen MazidiClinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ioanna Gouni-BertholdCenter for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Peter E PensonSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Dan GaitaInstitute for Cardiovascular Diseases, University of Medicine and Pharmacy Victor Babes, Research Center IBCVTIM, Timisoara, Romania.
Arrigo F G CiceroHypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy.
International Lipid Expert Panel (ILEP)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD), is the most common cause of death worldwide. Despite decades of research into lifestyle factors and medications, we still cannot effectively prevent the occurrence of ASCVD or the many incident CVD events and their complications. Yet, in most countries, only a small percentage of the healthcare budget is allocated to (primary) prevention, and only a few nations have introduced effective integrated (coordinated) programmes in primary prevention to promote health education, invest in health as early as possible, and prevent adverse CVD events. The International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE) responds to this significant ineffectiveness by offering the most comprehensive population approach, including early, effective education, improvement of all recognised risk factors, alongside those that remain frequently unmeasured, such as lipoprotein(a), factors which are often overlooked such as sleep disturbances and alcohol consumption, and the challenging aspect of stress, and its effect on cardiovascular health. Finally, ILEP-SMILE places considerable emphasis on adherence as a result of education; without it, even efficient lifestyle changes and the most innovative drugs may not yield the expected outcomes. This is also a loud call to action and international collaboration to jointly address the lifetime burden of cardiovascular disease.

Indexed as

alcohol consumptioncardiovascular risk factorsdieteducationexerciseInternational Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE)lipid disorderssleep disturbances

Identifiers

PMID40741254
PMCPMC12305506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.